hy0001a

mAbexperimentalADC

Clinical trial activity

2 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jul 10, 2025 (NCT07069062)

Timeline

2020s

  1. Jan 1, 2025

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Payload
MMAE

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07265206Early Phase 1 (Phase 1)Dec 30, 2025Capital Medical University, Juventas Therapeutics, Inc.
NCT07069062Phase 1/Phase 2 (Phase 2)Jul 10, 2025Government of China, Peking University
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Capital Medical UniversityAcademic/Hospital1012025
Government of ChinaGovernment1112025
Juventas Therapeutics, Inc.For profit1112025
Peking UniversityAcademic/Hospital1012025
4 organizations
Page 1 / 1